Yesterday, the Ninth Circuit issued an opinion affirming the dismissal of plaintiffs' consolidated complaint in In re Musical Instruments and Equipment Antitrust Litigation.

The Pennsylvania Employees Benefit Trust Fund recently filed a purported class-action antitrust complaint relating to the brand name drug Opana ER.

We have previously posted about the New York Attorney General's "product hopping" suit against Actavis and its subsidiary, Forest Laboratories LLC.

On Monday, the United States Court of Appeals for the Second Circuit heard oral argument in Apple’s appeal in the e-book price-fixing lawsuit brought by the Department of Justice.

We’ve previously discussed this appeal, which concerns Motorola’s claims arising from a foreign conspiracy to fix the price of LCD panels.

Two former executives of K-Line pleaded guilty and received prison sentences in February 2015.

On January 21, 2015, the Supreme Court of the United States issued a highly anticipated decision in a LIBOR-based antitrust class action suit allowing a plaintiff to immediately take a direct appeal from an order dismissing that plaintiff’s complaint ..

Today the United States Supreme Court denied certiorari in two cases, Motorola Mobility LLC v. AU Optronics et al. and Hsiung and AU Optronics Corp. America Inc. v. United States.

A few tax considerations are at play if one is donating an interest in a GP or management company, warn tax experts Dahlia Doumar and Carl Merino.

It is also critical to develop a plan for responding to a cyberattack or data breach before it happens.

In a short per curiam opinion in United States v. Lobo (Parker, Hall, Lohier), the Second Circuit affirmed the imposition of a Guidelines enhancement based on the importation of a controlled substance into the United States.

Hospira's proposed biosimilar has not been licensed by FDA.

This morning, the full Federal Circuit declined to rehear en banc Amgen v. Sandoz, the first appellate decision interpreting the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

The issues raised in Hospira's motion to dismiss are currently before the Federal Circuit in Amgen's and Sandoz's petitions for rehearing en banc.

In Amgen v. Apotex, Judge Cohn of the Southern District of Florida recently enjoined Apotex from selling its proposed biosimilar of Amgen's Neulasta for 180 days following FDA approval.

The exclusivity period for biologic drugs has recently become a hot topic in both domestic and foreign policy.

Bankruptcy plans often include provisions releasing debtors and their officers and directors from certain potential liability.

On September 5, 2018, Chief United States District Judge Colleen McMahon (S.D.N.Y.) issued a decision denying Plaintiff GeigTech's motion for preliminary injunction in its patent and trade dress infringement suit against Defendant Lutron.

As we previously reported, Capital One Financial Corporation announced in July 2019 a major data security breach when an individual gained unauthorized access to personal information about Capital One credit card customers.

In Accenture's 2018 State of Cyber Resilience for Banking & Capital Markets study, the consulting firm reported the rate at which cyber-attacks on banking and capital markets firms are successful dropped from 36 percent in 2017 to 15 percent in 2018.